|
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical research trials and A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. clinical trial. Participants oftentimes recieve the finest healthcare available for their A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.  A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
For Condition: Pancreatic Neoplasms,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body. - You must have one tumor that can be physically measured or scanned by the doctor. - You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU. - You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis. Exclusion Criteria: - Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study. - Documentation that the cancer has spread to your brain. - Pregnant or breastfeeding. - A second primary cancer. - Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 5148;
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035035
Other Pancreatic Neoplasms Studies:
1. Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent with Metastatic Lung Cancer
2. Iressa Expanded Access Program (EAP)
3. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
4. A Trial of ABI-007 in Patients with Advanced Non-Hematologic Malignancies
5. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
Related Studies:
Other Pancreatic Neoplasms Clinical Trials
Other California Clinical Trials
Other Pomona Clinical Trials
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
|
|
|
|
|
|
|
|
